Abbott
dominating the massive POC and continuous glucose monitoring (CGM) consumer markets.
- Country
- United States
- Ticker
- ABT
point-of-care
us
legacy
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Diagnostics & biosensors | diagnostics-medtech | Low | → |
| Point-of-care molecular diagnostics | diagnostics-medtech | Low | → |
| Wearable biodiagnostics | diagnostics-medtech | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.